Anti-SLAMF7 IgG binds SLAMF7 on tumor cells and engages effector cells via Fc to trigger NK cell–mediated ADCC; it can also activate complement (CDC) and promote antibody-dependent cellular phagocytosis (ADCP), leading to target-cell death.